Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $102.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $102.3 million, down 38.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $498.4 million (down 34.72% YoY), and the FY2025 annual result was $122.7 million, down 27.18% from the prior year.
• Non-Current Assets came in at $102.3 million for Q1 2026 at Ironwood Pharmaceuticals, down from $122.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $373.3 million in Q1 2022 to a low of $102.3 million in Q1 2026.
• The 5-year median for Non-Current Assets is $230.6 million (2024), against an average of $233.4 million.
• Across the five-year window, Non-Current Assets jumped 510.95% in 2022 and slumped 42.05% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Non-Current Assets stood at $319.9 million in 2022, then retreated by 25.67% to $237.8 million in 2023, then dropped by 29.12% to $168.5 million in 2024, then retreated by 27.18% to $122.7 million in 2025, then decreased by 16.66% to $102.3 million in 2026.
• The last three Non-Current Assets figures came in at $102.3 million (Q1 2026), $122.7 million (Q4 2025), and $122.2 million (Q3 2025), per Business Quant data.